BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Keryx Biopharmaceuticals (KERX) Announces Upcoming Poster Presentations of Zerenex(TM) (ferric citrate) at National Kidney Foundation (NKF) 2012 Spring Clinical Meetings


5/9/2012 11:54:58 AM

NEW YORK, May 9, 2012 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two abstracts highlighting potential cost savings based on clinical observations from prior clinical trials of Zerenex (ferric citrate), have been accepted for poster presentation at the upcoming National Kidney Foundation (NKF) 2012 Spring Clinical Meetings, taking place May 9-13, 2012, in Washington, DC.

The following posters will be presented by DaVita Clinical Research (DCR). The research was commissioned by Keryx and performed by DCR for presentation at the NKF meeting on Thursday, May 10, 2012, from 6:00pm-7:30pm:

  • Reduced Use of Erythropoiesis-Stimulating Agents and Intravenous Iron with Ferric Citrate: A Medicare Bundle Cost-Offset Model (Abstract # 337)
  • Reduced Use of Erythropoiesis-Simulating Agents and Intravenous Iron with Ferric Citrate: A Managed Care Cost-Offset Model (Abstract #338)

Zerenex, the Company's oral, ferric iron-based drug candidate for the treatment of hyperphosphatemia in end stage renal disease patients on dialysis, is currently in Phase 3 clinical development pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. The Zerenex Phase 3 registration program is comprised of an already successfully completed Phase 3 short-term study, and an ongoing Phase 3 long-term study.

Keryx holds a worldwide license (except for certain Asian Pacific countries) to Zerenex (ferric citrate) from Panion & BF Biotech, Inc. The Japanese rights are sublicensed by Keryx to Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for Zerenex (ferric citrate) may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability, and our Japanese partner's ability, to successfully and cost-effectively complete clinical trials for Zerenex (ferric citrate); the risk that the data (both safety and efficacy) from the ongoing Phase 3 trials for Zerenex (ferric citrate) will not coincide with the data analyses from previous clinical trials reported by us and our Japanese partner; our ability to meet anticipated development timelines for Zerenex due to clinical trial results, manufacturing capabilities or other factors; our ability to replicate in our ongoing long-term Phase 3 clinical study the effects on intravenous (IV) iron and erythropoiesis-stimulating agent (ESA) use observed in previous clinical trials; the ability for Zerenex to generate cost savings for dialysis centers, Medicare and managed-care payers; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

KERYX CONTACT:
Lauren Fischer
Director Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES